



# OHIO DEPARTMENT OF HEALTH

246 North High Street  
Columbus, Ohio 43215

614/466-3543  
www.odh.ohio.gov

John R. Kasich/Governor

Theodore E. Wymyslo, M.D./Director of Health

Peter Robinson, QA Director  
Quest Diagnostics Nichols Inst. of Valencia, Inc.  
27027 Tourney Rd.  
Valencia, CA 91355

RE: Clinical Lead Laboratory Approval Number C10061

Dear Peter Robinson:

The Ohio Department of Health (ODH) Lead Poisoning Prevention Program has reviewed your Clinical Lead Laboratory application. Your laboratory has met all of the criteria for approval as specified in Chapter 3701-82 of the Ohio Administrative Code (O.A.C.). Your laboratory approval number is C10061. The approval will expire on 11/9/2012.

O.A.C. 3701-82-02 (G) requires you to notify ODH within twenty four hours if for any reason your Clinical Laboratory Improvement Amendment (CLIA) accreditation is denied, revoked, suspended or limited. Additionally, you shall notify ODH within five business days each time the laboratory's CLIA accreditation as a clinical laboratory is renewed or modified. O.A.C. 3701-32-14 (B) requires you to submit a copy of your tri-annual lead proficiency testing results to ODH within five business days of receiving the results.

Please submit the above required information by one of the following methods; first class mail to the address listed below, electronic mail at [lead@odh.ohio.gov](mailto:lead@odh.ohio.gov), or facsimile to 614-564-2479.

Ohio Department of Health  
DQA, Lead Poisoning Prevention Program  
246 North High Street  
Columbus, OH 43215

In addition, you are required to comply with the electronic reporting requirements outlined in O.A.C. 3701-30-05. Questions regarding this reporting should be directed to the Surveillance Coordinator for the Childhood Lead Poisoning Prevention Program at (800) 532-3723.

In accordance with Chapter 119. of the Revised Code and O.A.C. 3701-82-02 (K), I may propose to refuse to issue or revoke the approval of any Clinical Lead Laboratory if at any time the laboratory does not meet the requirements of the O.A.C. or Chapter 3742. of the Revised Code.

If you have any questions about this approval letter, please contact David Holston at (877) 668-5323.

Sincerely,

A handwritten signature in black ink, appearing to read 'Theodore E. Wymyslo', is written over a faint, larger version of the signature.

Theodore E. Wymyslo, MD  
Director of Health